22.05SEK+3.76%Mkt Cap: 1.51B SEKP/E: —Last update: 2026-05-13
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-5.85
PEG0.27
P/B3.45
P/S6.95
EV/EBITDA-3.14
EV/Revenue4.89
EPS (TTM)-5.10
EPS (Forward)-3.93
Cash Flow & Leverage
FCF Yield-10.61%
FCF Margin-73.68%
Operating CF-247.75M SEK
CapEx (TTM)7.26M SEK
Net Debt/EBITDA1.33
Net Debt-450.22M SEK
Technical
SMA 5022.48 (-1.9%)
SMA 20027.78 (-20.6%)
Beta—
S&P 52W Chg24.23%
Avg Vol (30d)107.25K
Avg Vol (10d)202.93K
Technical Indicators
RSI (14)47.2
MACD-0.1086
MACD Signal-0.1538
MACD Hist.+0.0452
BB Upper23.35 SEK
BB Middle22.27 SEK
BB Lower21.20 SEK
BB Width9.64%
ATR (14)1.035 SEK
Vol Ratio (20d)1.99x
52W Range
20.856% of range41.60
52W High41.60 SEK
52W Low20.85 SEK
Profitability
Gross Margin100.00%
EBITDA Margin-155.52%
Profit Margin-146.96%
Oper. Margin-907.23%
ROE-59.69%
ROA-49.59%
Revenue Growth-39.20%
Earnings Growth—
Balance Sheet
Debt/Equity0.02
Current Ratio5.32
Quick Ratio5.20
Book Value/Sh6.666 SEK
Cash/Share6.930 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateDec 14, 2020
Ownership
Shares Out.65.80M
Float31.48M
Insiders12.89%
Institutions55.54%
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)95.00 SEK
Target Range85.00 SEK – 110.00 SEK
# Analysts3
Company
Market Cap1.51B SEK
Enterprise Value1.06B SEK
Revenue (TTM)217.86M SEK
Gross Profit217.86M SEK
Net Income (TTM)-332.86M SEK
Revenue/Share3.311 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees109
Last Price22.05 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0015244520